Acadia Pharmaceuticals (ACAD) Gross Margin (2016 - 2026)
Acadia Pharmaceuticals (ACAD) posted quarterly Gross Margin of 90.75% for Q1 2026, down 90.0% year-over-year from 907.52% in Q1 2025, and little changed quarter-over-quarter from 90.77% in Q4 2025.
Acadia Pharmaceuticals (ACAD) Gross Margin (2016 - 2026) Analysis & Trends
Acadia Pharmaceuticals' Gross Margin history runs 11 years deep, the most recent figure standing at 90.75% for Q1 2026.
- In Q1 2026, Gross Margin fell 90.0% year-over-year to 90.75%; the TTM figure through Mar 2026 stood at 91.47% (down 57.0% YoY), while the FY2025 annual figure was 91.69%, up 24.0% from the prior year.
- Gross Margin for Q1 2026 stood at 90.75%, roughly flat from 90.77% in the prior quarter.
- The five-year high for Gross Margin was 98.59% in Q1 2023, with the low at 88.85% in Q1 2024.
- The 5-year median for Gross Margin is 92.47% (2024), against an average of 93.79%.
- The sharpest annual moves came in 2022 and 2024: Gross Margin surged 645 bps in 2022, then tumbled 974 bps in 2024.
- Acadia Pharmaceuticals' Gross Margin stood at 98.23% in 2022, then fell by 6 bps to 92.26% in 2023, then retreated by 1 bps to 91.6% in 2024, then declined by 1 bps to 90.77% in 2025, then dropped by 0 bps to 90.75% in 2026.
- Business Quant data shows ACAD's Gross Margin at 90.75% in Q1 2026, 90.77% in Q4 2025, and 92.23% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 85.33% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 91.59% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 90.68% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 89.76% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 60,631,834.75% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 76.90% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 84.20% |
| 10 | Acadia Pharmaceuticals | 4.86 Bn | 3.90 Bn | 279.64 Mn | 90.81% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 90.81% |
| Mar 31, 2026 | 90.75% |
| Dec 31, 2025 | 90.77% |
| Sep 30, 2025 | 92.23% |
| Jun 30, 2025 | 92.16% |
| Mar 31, 2025 | 91.65% |
| Dec 31, 2024 | 91.60% |
| Sep 30, 2024 | 92.47% |
| Jun 30, 2024 | 92.47% |
| Mar 31, 2024 | 88.85% |
| Dec 31, 2023 | 92.26% |
| Sep 30, 2023 | 93.09% |
| Jun 30, 2023 | 95.49% |
| Mar 31, 2023 | 98.59% |
| Dec 31, 2022 | 98.23% |
| Sep 30, 2022 | 98.37% |
| Jun 30, 2022 | 98.02% |
| Mar 31, 2022 | 97.45% |
| Dec 31, 2021 | 91.78% |
| Sep 30, 2021 | 97.20% |